Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet
Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary
Artery Disease

Inclusion Criteria:

- Documented stable CAD fulfilling any of the following, and taking 81mg ASA daily
treatment:

- Females must be post menopausal for at least one year or surgically sterile for at
least 6 months and negative urine pregnancy test

- Self-identified as American Indian

- Genetic Inclusion Criteria: must sign the informed consent for genetic and biological
sample banking.

Exclusion Criteria:

- Any indication for oral anticoagulant or dual antiplatelet treatment

- Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow
therapeutic index, or strong CYP3A inducers within 14 days and during study treatment
and during:

- Increased bleeding risk including:

- Diabetic patients with HbAlC > 10% at screening

- Contraindication to clopidogrel, ASA, or ticagrelor - A history of alcohol and/or
substance abuse that could interfere with conduct of the trial

- Patients requiring dialysis

- Patients scheduled for revascularization (e.g., PCI, CABG) during the study period

- Any acute or chronic unstable condition in the past 30 days

- Known active or recurrent hepatic disorder

- Patients who had ACS or stent placed within 12 months of screening

- History of Uric Acid nephropathy